NCT00387621View on ClinicalTrials.gov

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2009

Conditions
Congestive Heart Failure
Interventions
DRUG

Nesiritide

The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.

DRUG

Placebo

The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.

DRUG

Saline

Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Horng Chen

OTHER

NCT00387621 - Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction | Biotech Hunter | Biotech Hunter